Mark Haverick

Mark Haverick joined Merck Biologics development in 2011 as part of the analytical method development group. Mark received B.S. in Biochemistry from Montclair State University in 2009 and his M.S. in Chemistry from The Ohio State University in 2011, where his research focused on the synthesis, purification, and characterization of self-assembling peptide amphiphiles for use as MRI imaging agents in cancer diagnostics. Mark’s technical contributions to the Merck biologics pipeline have been focused on chromatography-based methods (SEC, HIC, IEX) and capillary electrophoresis based methods supporting both early and late-stage compounds. During his tenure at Merck, he has supported various modalities including mAbs, fusion proteins, nanobodies, and co-formulated products as well as recombinant vaccines and mRNA-LNP vaccines. Mark’s research interests focus on expanding the CMC analytical toolkit for enhanced characterization of therapeutic proteins focused on deeper product understanding to enable improved product stability.

Appearances